GSA Capital Partners LLP Purchases Shares of 852,852 PepGen, Inc. $PEPG

GSA Capital Partners LLP purchased a new position in shares of PepGen, Inc. (NASDAQ:PEPG) during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 852,852 shares of the company’s stock, valued at approximately $1,535,000.

A number of other institutional investors also recently made changes to their positions in PEPG. RA Capital Management L.P. grew its holdings in shares of PepGen by 87.7% during the 3rd quarter. RA Capital Management L.P. now owns 20,064,545 shares of the company’s stock valued at $92,698,000 after purchasing an additional 9,375,000 shares during the last quarter. Vivo Capital LLC purchased a new position in PepGen in the 3rd quarter worth $10,742,000. Viking Global Investors LP lifted its stake in PepGen by 134.9% in the third quarter. Viking Global Investors LP now owns 3,482,434 shares of the company’s stock worth $16,089,000 after purchasing an additional 2,000,000 shares during the last quarter. ADAR1 Capital Management LLC lifted its stake in PepGen by 4,263.6% in the first quarter. ADAR1 Capital Management LLC now owns 1,607,638 shares of the company’s stock worth $2,846,000 after purchasing an additional 1,570,796 shares during the last quarter. Finally, Nantahala Capital Management LLC purchased a new stake in PepGen during the fourth quarter valued at about $10,072,000. Hedge funds and other institutional investors own 58.01% of the company’s stock.

PepGen Stock Performance

Shares of NASDAQ:PEPG opened at $2.99 on Monday. The company has a market cap of $207.09 million, a price-to-earnings ratio of -2.28 and a beta of 1.89. The company has a 50-day moving average price of $2.01 and a 200-day moving average price of $3.02. PepGen, Inc. has a 12 month low of $1.13 and a 12 month high of $7.80.

PepGen (NASDAQ:PEPG) last posted its earnings results on Thursday, August 6th. The company reported ($0.26) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.28) by $0.02. As a group, research analysts forecast that PepGen, Inc. will post -1.11 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of research analysts have recently issued reports on PEPG shares. Wall Street Zen raised PepGen from a “sell” rating to a “hold” rating in a research note on Sunday, June 7th. Weiss Ratings lowered PepGen from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Tuesday, June 2nd. HC Wainwright restated a “buy” rating on shares of PepGen in a report on Thursday, May 21st. Craig Hallum began coverage on PepGen in a research report on Tuesday, June 16th. They set a “buy” rating and a $11.00 price target on the stock. Finally, Wedbush decreased their price target on PepGen from $5.00 to $4.00 and set an “outperform” rating on the stock in a research note on Wednesday, May 13th. Six research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $11.50.

About PepGen

PepGen, Inc (NASDAQ: PEPG) is a clinical-stage biotechnology company headquartered in San Diego, California. The company is developing precision gene editing therapies to address rare genetic diseases by combining advanced prime editing modalities with proprietary delivery technologies. PepGen’s platform is designed to achieve targeted and durable correction of disease-causing mutations in vivo, with the goal of providing long-lasting therapeutic benefit after a single administration.

The company’s lead development programs include PPG-001 for mucopolysaccharidosis type II (Hunter syndrome) and PPG-002 for mucopolysaccharidosis type I (Hurler syndrome).